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Genetic variation of the Bovine Leukemia Virus (BLV) appears to be limited in vitro and during the latent phase of the 
disease. However, cells in tumors often harbor deleted proviruses that are defective for expression. In order to gain insight 
into the involvement of viral genetic variation during pathogenesis, the BLV LTR and the env proviral sequences were 
analyzed in tumor tissues. A sheep (M230) was injected with the cloned BLV provirus 344 and became persistently infected 
with circulating lymphocytes reaching 345,000/mm a. After 11 months, this infected sheep developed leukemia-lymphoma. 
DNA was extracted from peripheral blood leukocytes at the time of tumor development and the LTR and the env gene were 
amplified, using the polymerase chain reaction procedure, cloned, and sequenced..Twenty independent LTR and twenty env 
clones were analyzed. It appeared that the in vivo mutation rate in the env gene was 0.043% (eight mutations including 
seven transitions out of 18,300 bp). Five point mutations (all transitions) were identified in the LTR, corresponding to 0.041% 
modifications (four mutations out of 9740 bp). These mutation rate values (0.043 and 0.041) were close to those due to the 
Taq DNA polymerase rrors (0.030%). Altogether, these data demonstrate the lack of genetic variation in the LTR and the 
env gene during this case of BLV-induced pathogenesis n vivo. They confirm that the defectiveness of some BLV proviruses 
in vive, thus, is not a mandatory step in the leukemogenic process. © 1995 Academic Press, Inc. 
Little is known about the molecular events leading to 
BLV-induced leukemogenesis. BLV is exogenous to the 
bovine and ovine species and thus, does not contain a 
classical oncogene (reviewed in 1). The provirus seems 
to integrate at random in the genome of the infected cell. 
In vivo, most of the infected cells do not express viral 
information (2, 3). In vitro, some evidence indicates that 
the tax gene has immor[alizing functions in primary cells 
(4). BLV can naturally infect cattle and be experimentally 
transmitted to sheep where it induces leukemia/ 
lymphoma. The viral LTR and env  sequences do not 
seem to vary during the asymptomatic stage of the infec- 
tion (6). The nucleotide sequence of seven BLV env 
genes allowed the determination of a 6% variability be- 
tween various isolates. The variabilities within two geo- 
graphical groups were 0.7 and 1.5%, respectively (6). BLV 
has a main advantage for the study of genetic variation 
in the HTLV/BLV subgroup= direct in vivo experiments 
can be performed using molecularly cloned proviruses 
as infectious material. Using this protocol, the intrastrain 
variability of BLV was measured during infection in the 
absence of clinical symptoms (5). The in vivo mutation 
rate was 0.009 and 0.034% nucleotide changes/year in 
the env gene and in the LTR, respectively. These data 
demonstrated the extremely low level (or the absence) 
of intrastrain variability of BLV in vivo in asymptomatic 
animals. One parameter of this stability is the lower muta ~ 
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tion rate of the BLV reverse transcriptase (7). In vitro, the 
error rate of the reverse transcriptase (RT) is 4.8 × 10 ~ 
mutation per basepair per cycle (versus 1.2 X 10 -5 for 
the spleen necrosis virus RT). However, the in vivo muta- 
tion rate is the composite of three variables= the mutation 
rate per replication cycle, the number of replication cy- 
cles, and the selective advantage of the variant provi- 
ruses (7). In cattle, up to one-third of the proviruses har- 
bor deletions in the BLV-induced tumors (reviewed in 1). 
One of these proviruses (1345) deleted in most of the 
genome (extending from the p24 gag to the gp51 env coding 
sequences) was not infectious in vivo (8). Defective provi- 
ruses were also found in sheep. We previously reported 
that two sheep (344 and 395) originally infected with 
the same inoculum (blood from a BLV-infected cow 907) 
developed tumors harboring either a single infectious 
(344) or a single defective (395) provirus (8). Altogether, 
these data show a genetic variation during pathogenesis. 
The purpose of this study is to quantify this intrastrain 
variability of the BLV proviruses after a case of BLV cellu- 
lar transformation. 
Direct injection of proviral DNA into sheep has pro- 
vided a useful model for the study of genetic modifica- 
tions during pathogenesis. In order to analyze this vari- 
ability, a sheep (M230) was infected using a cloned BLV 
provirus. The recombinant vector pBLV344 contains an 
infectious BLV provirus isolated from a sheep tumor (8, 
9). ~ Plasmid DNA (100 #g) was mixed with 200 #g of 
a cationic lipid solution (DOTAP, N-(1-(2,3-Dioleeyloxy) 
propy l ) -N ,N ,N- t r imethy l -ammoniummethy lsu l fa te ,  Boeh- 
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ringer). This lipid forms unilamellar vesicles (liposomes) 
which interact with DNA to form stable complexes. The 
mixture was injected intradermally into sheep M230. 
Sera were collected weekly and analyzed for BLV sero- 
positivity by immunodiffusion and indirect gp51 ELISA 
(10, 11, 12). Antibodies directed to the extracellular enve- 
lope protein gp51 were detected as early as 1 month 
postinjection (9). Seroconversion was confirmed by im- 
munodiffusion, by anti-p24 ELISA (the major capsid pro- 
tein), and by PCR amplifications (data not shown). After 
seroconversion, the antibody titers rose gradually during 
20 weeks and reached a plateau (stabilized at a serum 
titer of 1/14,580, i.e., the dilution giving 0.150 OD). At the 
onset of leukemia (week 55), the titers peaked suddenly 
at 1/43,740. The evolution of the total leukocytes count 
was determined with a Coulter counter ZN. At the time 
of seroconversion, a small peak in the leukocyte counts 
was observed, 8800 versus 6300 leukocytes/mm 3.A de- 
tectable increase in the number of ieukocytes could be 
observed at Week 47 (14,000 leukocytes/mm3). Then, the 
leukocyte number rose gradually during 10 weeks to 
reach 345,000 leukocytes/mm 3 at the death of the animal. 
Southern blot analysis of peripheral blood mononuclear 
cells DNA using a BLV-specific probe revealed that a 
single and complete provirus was integrated in the geno ~ 
mic DNA (data not shown). 
Peripheral blood mononuclear cells (PBMCs) were iso- 
lated by density gradient centrifugation on FicoiI-Hy- 
paque (Histopaque; Sigma) from 200 ml of blood. Cells 
were cultured at a concentration of 4 x 106 per milliliter 
of RPMI 1640 (GibcoBRL) supplemented with penicillin 
(100 U/ml), streptomycin (100 #g/ml), h-glutamine (4 mM), 
10% heat-inactivated fetal calf serum (GibcoBRL) and 10 
#g/ml phytohemagglutinin. Supernatant from S-day 
PBMC cultures was precipitated by ammonium sulfate 
overnight at 4 °. The p24 major gag antigen was titrated 
from the supernatant using the ELISA procedure as pre- 
viously described (23, 24). Briefly, 96-well microtiter 
plates were precoated with the anti-p24 4'G9 monoclonal 
antibody. The antigen mixture to be tested was then 
added to the wells. After washing, the p24 antigen was 
revealed by colorimetric assay using two antibodies 
(2'C1 and 4'F5) conjugated with peroxydase. The amount 
of p24 in the supernatant was estimated at 1.5 mg/ml 
after 5 days of culture. This strongly suggests that viral 
particles are produced in the culture medium and that 
the proviruses infecting animal 230 were not defective. 
The experimental strategy used in this study of BLV 
genetic variation is based on sequencing of individual 
clones corresponding to viral genes. Two regions were 
analyzed, (i) the env gene because the envelope glyco- 
proteins play a crucial role in the replication cycle and 
in cellular tropism (13-17). Their location at the surface 
of the viral particle explains why they are targets for 
neutralizing antibodies. (ii) The LTR contains the regula- 
tory sequences involved in viral expression. The U3 re- 
gion of the LTR is also involved in determining tissue 
tropism and tumorigenicity (18). 
Before postmortem examination of sheep 230, a single 
500-#1 blood sample was used for PCR amplifications 
(as previously described in 5). The LTR sequences were 
amplified using primers LTRB (position -189 to -167 
(19, 20)= 5' TAGGCGCCGCCACCGCCCCGTAA 3') and 
LTRD (position 366 to 344, 5' GGATCGTTAGGG-i-FC- 
CGGGGTGA 3'). For the env gene, primers ENVC (posi- 
tion 4590 to 4612= 5' CCTGGCG-FFI-GCTAAAAGCC-FF 3') 
and ENVD (position 5549 to 5527, 5' GCTAGGCCTAAG- 
GTCAGGGCTGC 3') were used. The viral sequences 
were amplified by 36 cycles of PCR (30 sec at 94 ° , 1 min 
at 55 ° and 2 min at 72°). After PCR amplification, the 
samples were analyzed by Southern blot hybridization 
using a BLV-specific probe (data not shown). As a control 
for PCR contamination, a similar protocol was applied 
using blood from a BLV-negative sheep. LTR- and env- 
specific fragments (0.6 and 1.0 kb, respectively) were 
isolated by agarose gel electrophoresis and cloned into 
the pGem7 plasmid. Nucleotide sequence analysis was 
performed using the T7- and SP6-specific primers, E4760 
(5' TGACAACATATAACCAAGA 3'), E4960 (5' TTATGT- 
GGGGGCAGATCAC 3'), E5160 (5' OCGACTTCCCTC- 
AGCTGAA 3'), and E5360 (5' TGGGTCAACACGTOO- 
TTGT 3'). Twenty LTR and 20 env clones (each derived 
from two independent PCR amplifications) were isolated 
and sequenced. For each clone, the LTR sequences were 
analyzed from position -167 to +321 (position 1 corre- 
sponds to the cap site, (19, 20)). The nucleotide sequence 
of the provirus 344 LTR is presented in Fig. 1. Among 
the 20 LTR clones analyzed, four point mutations of 9740 
bp were identified. All these modifications were transi- 
tions, C ~ T at position -129, T ~ C at position 259, 
A ~ G at position -37, and G ~ A at position -7. In vivo, 
the mutation rate was thus 0.049% nucleotide changes 
in the LTR. A similar mutation rate (0.043%) was mea- 
sured for the env gene (eight mutations out of 18,300 bp 
sequenced) (Fig. 2). Most of the modifications (7/8) were 
transitions= C --* T (at positions 4645, 5048), G ~ A (at 
positions 4649, 4669, 5139, 5428, and 5443). One trans- 
version (C -~ G) was identified at position 5404. These 
mutation rate values are close to the level of Taq DNA 
polymerase errors (0.030%) measured in a previous study 
(5). Furthermore, the different mutations were not con- 
served among the various clones, i.e., each base change 
occurred only once among all 20 clones. 
Our results extend our previous report on the lack of 
intrastrain variability during the asymptomatic phase and 
illustrate the limited genetic variation in the LTR and the 
env gene even during BLV-induced pathogenesis in vivo. 
This low level of variation could result from the high 
fidelity of cellular DNA synthesis during monoclonal out- 
growth of the tumor cell having integrated one of many 
BLV proviruses produced during persistent viral replica- 
tion in the circulating pBMCs. Circular unintegrated pro- 
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TOTATGAAAG ATCATGCCGG CCTAGGCGCC GCCACCGCCC CGTA.AACCAG 
ACAGAGACGT CAGCTGCCAG AAAAGCTGGT GAC_GGCAGCT GGTGGCTAGA 
T(-129) 
ATCCCCGTAC CTCCCCAACT TCCCCTTTCC CGA.AAAATCC ACACCCCGAG 
CTGCTGACCT CACCTGCTGA TAAAA_CAATA AAATGCCGGC CCTGTCGAGT 
G(-37) 
$R 
TAGC_GGCACC AGAAGCGTTC TCCTCCTGAG ACCCTCGTGC TCAGCTCTCG 
A(-7) 
GTCCTGAGCT CTCTTGCTCC CGAGACCTTC TGGTCGGCTA TCCGGCAGCG 
GTCAGGTAAG GCAAACCACG GTTTGGAGGG TGGCTCTCGG CTGAGACCAC 
CGCGAGCTCT ATCTCCGGTC CTCTGACCGT CTCCACGTGG ACTCTCTCTC 
$U5 
TTGCCTCCTG ACCCCGCGCT CCAAGGGCGT CTGGCTTGCA CCCGCGCTTG 
TTTCCTGTCT TACTTTCTG_T TTCTCGCGGC CCGCGCTCTC TCCTTCGGCG 
C(259) 
LTR $ GAG 
CCCTCTAGCG GCCAGGAGAG ACCGGCAAAC AATTGG 
FIG. 1. Nucleotide sequence of the LTR sequence of provirus 344 
and individual variations. Twenty individual LTR clones were analyzed 
and compared to the pBLV344 sequences. Position 1 corresponds to 
the CAP site. 
viruses are intermediate forms that appear consecutively 
to infection and retrotranscription. Therefore, they reflect 
the extent of viral replication in vivo. DNA from circulating 
PBMOs was. extracted by the Hirt procedure (21) and 
PCR amplified using two primers, 260 (5' qq-CTOGOGG- 
0COGOGOTCTOT3') and 2240 (5'GCCAGAOGOCCT- 
TGGAGCGO3'). These primers located in the U5 and U3 
regions, respectively, can amplify junctions between two 
linked LTRs. When DNA from a virus expressing cell line 
(FLK, foetal lamb kidney cells) was POR amplified, a 500- 
bp fragment was obtained as expected (Fig. 3, lane 4). 
As a control, no product was amplified using uninfected 
OVK cell DNA (Fig. 3, lane 5). The two LTR circles could 
not be amplified neither from the tumorigenic YR2 cell 
line DNA nor from a naturally-occurred tumor DNA (lanes 
2 and 1, respectively). These results corroborate the lack 
of viral replication in BLV-transformed cells. Hirt superna- 
tant DNA extracted from sheep 230 PBMCs yielded the 
500-bp amplification product demonstrating that viral 
replications occurred in the circulating lymphocytes (Fig. 
3, lane 3). These PCR amplifications together with the 
high levels of viral expression after short term culture 
demonstrate that replication did occur in the sample ana- 
lyzed for genetic variability. 
The high degree of conservation in the BLV envelope 
sequences could result from high evolutionary con- 
straints maintaining the protein functions. As such, muta- 
genesis of the envelope proteins of the HTLV virus 
revealed that their functions are disrupted by most 
changes (22). 
CGCCCTCCTG GCTACTAACC CCCCCGTGTG GGTTCCCTGGCGTTTGCTAA 
4555 
SGP51-+ G(4649) 
AA.GCCTTCAA ATGCCCAAAG AACGACGGTC CCGAAGACGC CCACAACCGA 
4605 T(4645) 
TCATCAGATG GGTAAGTCTC ACTCTTACTC TCCTCGCTCT CTGTCAGCCC 
4655 G(4669) 
ATCCAGACTT GGAGATGCTC CCTGTCCCTA GGAAATCAACAATGGATGAC 
4705 
A-&CATATAAC CAAGAGGCAA AATTTTCCAT CGCCATTGAC CAAATACTAG 
4755 
AGGCTCAT,~A TCAATCGCCT TTCTGTCCCA GGTCTCCCAG ATACACCTTG 
4805 
GACTTTGTAAATGGTTATCC TAAGATCTAT GGCCCCCCC CACAAGGGCG 
4855 
ACGCCGGTTT GGAGCCAGGGCCATGGTCAC ATATGATTGC GAGCCCCGAT 
4905 
GCCCTTATGT GGGGGCAGAT CACTTCGACT GCCCCCACTG GGACAATGCT 
4955 
TCCCAGGCCG ATCAAGGGTC CTTTTATGTCAATCATCAGA TTT!ATTCCT 
5005 C(5048) 
GCATCTCA-AACAATGTCATG GA~.TTTTCAC TCTAACCTGG GAAATATGGG 
5055 
GATATGATCC CCTGATCACC TTTTCTTTAC AT~TCCC TGATCCCCCT 
5105 G(5t39) 
CAACCCGACT TCCCTCAGCT GAACAGTGAC TGGGTTCCCT CTGTCAGGTC 
5156 
ATGGGCCCTG CTTTTAAATCAAACGGCACG GGCCTTCCCA GACTGTGCTA 
5205 
TATGTTGGGA ACCTTCCCCT CCCTGGGCTC CCGAAATATT AGTATATAA.C 
5255 
AAAACCATCT CCAACTCTGG ACCCGGTCTC GCCCTCCCGG ACGCCCAAAT 
53O5 
CTTCTGGGTC AACACGTCCT TGTTTAACAC CACCCAAGGA TGGCACCACC 
5355 G(5404) 
CTTCCCAGAG GTTGTTGTTCAAC_GTTTCTCAAGGCAACGC CTTATTATTA 
5405 A(5428) A(5443) 
CCCCCTATCT CCCTGGTTAATCTCTCTACGGCTTCCTCCG CCCCTCCTAC 
5455 
SGP30--> 




FIG. 2. Nucleotide sequence variations in the env  gene of provirus 
344. Twenty env  clones were analyzed and compared to the pBLV344 
sequences. The positions of the mutations in the different clones are 
referred to the sequence determined by Rice et  al, (19, 20). 
1 2 3 4 5 
FIG. 3. PCR amplifications of unintegrated proviral DNA sequences. 
The 260 and 2240 primers used are located in the U5 region of the 
LTR at positions 260 and 2240 (19, 20). The DNAs were extracted from 
a BLV-induced tumor.(210) (lane 1), a transformed cell line (YR2) (lane 
2), sheep 230 PBMCs (lane 3), the BLV-infected FLK cells (lane 4), and 
OVK cells (lane 5). 
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The continued presence of virus is equated with a 
partial or total malfunction of the appropriate immune 
response. In evolving strategies to accomplish persis- 
tence, viruses have developed a number of tricks (23- 
30): (i) avoiding immunological surveillance by removing 
the recognition molecules on the infected cell, abrogat- 
ing lymphocyte/macrophage function (immunosuppres- 
sion), or hiding in cells lacking MHC expression (neu- 
rons); (ii) establishing a nonlytic phase of viral replication, 
generation of mutants or lack of viral gene expression. 
Several strategies could be used by BLV; the virus in- 
duces immunosuppression in rabbits and is mainly silent 
in the infected host (reviewed in 1). However, our data 
show that an escape mutant strategy does not seem to 
be involved during BLV pathogenesis. 
A mutation in the viral genome can affect the persis- 
tence of the virus in the host. One issue concerns the 
evolutionary survival of the virus; one given mutation may 
affect viral replication and its continued existence as an 
entity capable of infecting new hosts. The other issue is 
the survival of the infected cell and the development of 
a tumor in the persistently infected host. A replication 
defective virus may escape the host immune response 
but is an evolutionary dead end for the virus. 
The in vivo mutation rate of a retrovirus is the compos- 
ite of three variables, the mutation rate per replication 
cycle, the number of replication cycles, and the selective 
advantage of the variant proviruses (7). Mutations may 
lead to the destruction of the viral infectious potential. 
Defective prov/ruses are frequently found both in cattle 
and in sheep. These proviruses are not infectious (virus 
395) or even completely silent in vitro (1345) (8). The lack 
of viral expression could confer a selective advantage to 
the cell harboring a defective provirus. An infected cell, 
once transformed, should be hiding in the absence of 
viral gene expression. This suggests a strategy for es- 
caping the host immune system during pathogenesis. 
However, our experiments confirm that the defectiveness 
of BLV proviruses in vivo, although frequent, is not a 
mandatory step in leukemogenesis, but once occurring, 
might help the infected cell to escape immunosurveil- 
lance. 
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